

Updated: 08/2020 DMMA Approved: 08/2020

HEALTH OPTIONS DMMA Request for Prior Authorization for Aloxi (palonosetron) Website Form – <u>www.highmarkhealthoptions.com</u> Submit request via: Fax - 1-855-476-4158

All requests for Aloxi (palonosetron) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

## Aloxi (palonosetron) Prior Authorization Criteria:

Coverage may be provided with a <u>diagnosis</u> of postoperative nausea and vomiting and the following criteria is met:

- The member must be 18 years of age or older
- Must provide documentation showing the member has tried and failed (which will be verified via pharmacy claims if available) or had an intolerance or contraindication to Ondansetron
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Duration of Approval:** 3 months

Coverage may be provided with a <u>diagnosis</u> of chemotherapy-induced nausea and vomiting and the following criteria is met:

- The member must be 1 month of age or older
- Must meet one of the following:
  - If Aloxi will be used in combination with Dexamethasone without a Neurokinin 1 receptor antagonist, must provide documentation showing the member has tried and failed (which will be verified via pharmacy claims if available) or had an intolerance or contraindication to Granisetron (may require prior authorization)
  - In all other antiemetic regimens, must provide documentation showing the member has tried and failed (which will be verified via pharmacy claims if available) or had an intolerance or contraindication to Ondansetron
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.



Updated: 08/2020 DMMA Approved: 08/2020

ALOXI (PALONOSETRON)
PRIOR AUTHORIZATION FORM

	requested information below		s notes, laboratory test results,			
	ded, you may call to speak to		ervices. <b>FAX:</b> (855) 476-4158 Representative.			
	<b>DNE</b> : (844) 325-6251 Monda	ay through Friday 8:30				
	<b>PROVIDER</b> 1	INFORMATION				
Requesting Provider:		NPI:				
Provider Specialty:		Office Co				
Office Address: Office P						
		Office Fai	X:			
Member Name:	MEMBERI	NFORMATION DOB:				
Health Options ID:			Member weight:pounds orkg			
Theatin Options ID.	<b>REOUESTED DR</b>	UG INFORMATION	-	ĸg		
Aedication:			Strength:			
Frequency:			Duration:			
Is the member currently receiving	g requested medication?		Medication Initiated:			
Is this medication being used for				the life of		
the patient? Yes No	0					
		nformation				
This medication will be billed: $[$	at a pharmacy <b>OR</b>					
	medically (if medically pl					
Place of Service: Hospital		ember's home 🗌 Othe	er			
λ.Υ.	Place of Serv	vice Information				
Name:	NPI:					
Address:	Phone:					
	MEDICAL HISTORY (	Complete for ALL re	anosts)			
	MIEDICAL IIISTOKI (	complete for ALL re	aquests)			
agnosis: ICD-10:						
		102 107 _				
	CURRENT or PR	EVIOUS THERAPY	7			
Medication Name	Strength/ Frequency	<b>Dates of Therapy</b>	Status (Discontinued & W	hy/Current)		
SU	PPORTING INFORMATI	ON or CLINICAL R	ATIONALE			

Prescribing Provider Signature	Date